Key Highlights

  • Nine-month net loss was USD 7.2 million, as of September 30, 2026.
  • Cash and cash equivalents were USD 4.4 million at September 30, 2026.
  • Working capital was USD 4.2 million, against negative USD 3.3 million at year-end.
  • Financing included USD 13.1 million of net proceeds from share issuance.

Artelo Biosciences (NASDAQ:ARTL) reported loss per share of USD 3.19 for the third quarter of 2026, against an estimate of USD 7.02. The company is a clinical-stage biopharmaceutical company focused on therapeutics that target lipid-signaling pathways, including treatments intended to modulate the endocannabinoid system. It reported no revenue.

The company incurred a net loss of USD 7,153 thousand during the nine months ended September 30, 2026, and held cash and cash equivalents of USD 4,437 thousand at September 30, 2026. The filing includes a Going Concern section describing losses since inception.

Operating Expenses and Working Capital

The filing attributes the decrease in operating expenses for the three months ended September 30, 2026 primarily to a USD 0.7 million decrease in professional fees, mainly general and administrative. It also cites a USD 0.3 million decrease in other Research and Development expenses and a USD 0.3 million decrease in stock-based compensation, partly offset by an increase of less tha USD 0.1 million in employee and director compensation.

Total current Assets were USD 4.6 million at September 30, 2026, against USD 0.7 million at December 31, 2025. Current liabilities were USD 439 thousand, against USD 4,044 thousand. Working Capital was USD 4,157 thousand, against negative USD 3,349 thousand, a change of USD 7,506 thousand.

For the nine months ended September 30, 2025, cash used in Operating Activities was attributed primarily to a net loss of USD 8.7 million, offset by decreases in operating assets and increases in liabilities of USD 2.2 million and non-cash stock-based compensation of USD 0.8 million.

Financing Activities

During the nine months ended September 30, 2026, cash flows provided by financing activities included net proceeds from the issuance of common shares of USD 13.1 million, net proceeds from the issuance of convertible notes of USD 0.6 million and proceeds from the exercise of warrants of USD 0.2 million. These were offset by USD 1.2 million in repayments to holders of convertible notes.

On March 27, 2026, the company entered into a securities purchase agreement for a private placement. It covered 9,000 shares of common stock at USD 31.05 per share and pre-funded warrants to purchase 345,268 shares at an exercise price of USD 0.009 per share. The company also carried out a one-for-six Reverse Stock Split effective June 13, 2025, and its financial statements reflect it.

Product Candidates

The filing describes ART27.13 as a potential treatment for cancer-related anorexia, currently in a Phase 1b/2a trial called the Cancer Appetite Recovery Study, or CAReS. In an interim analysis of the ongoing Phase 2a CAReS trial, patients with cancer anorexia receiving ART27.13 showed a mean weight gain of over 6%, against a 5% loss in the placebo group. The safety profile was similar to the Phase 1b despite doses up to twice the previous maximum. The filing notes that there is currently no FDA-approved treatment for cancer anorexia cachexia syndrome.

ART27.13 is also being dosed in an investigator-led Phase 2 study in the United Kingdom evaluating patients with glaucoma or ocular hypertension.

The second program, ART12.11, is described as a wholly owned, proprietary cocrystal composition of cannabidiol and tetramethylpyrazine. The filing says it has exhibited better pharmacokinetics and improved efficacy compared with other forms of cannabidiol in nonclinical studies.

The reported items for the period are the nine-month net loss of USD 7,153 thousand, cash of USD 4,437 thousand, the March 2026 private Placement and the interim CAReS data. The company is listed on the Nasdaq Stock Market.